Table 3 Multivariate analysis of factors affecting Outcomes. A Multivariate analysis for factors affecting OS. B Multivariate analysis of factors affecting NRM. C Multivariate analysis of factors affecting PFS. D Multivariate analysis of factors affecting relapse. E Multivariate analysis of factors affecting graft failure.
A | Group | HR (95% CI) | p |
|---|---|---|---|
Donor (HD vs MSD) | <6 m | 1.93 (1.24–3) | 0.004 |
>6 m | 0.74 (0.44–1.26) | 0.3 | |
Donor age (dec) | <6 m | 1 (0.84–1.19) | 0.96 |
>6 m | 1.19 (1.02–1.4) | 0.026 | |
Donor x donor age | <6 m | 0.99 (0.78–1.25) | 0.9 |
>6 m | 0.76 (0.59–0.98) | 0.034 | |
Patient age (dec) | 1.04 (0.94–1.16) | 0.5 | |
WHO classification | RA/RARS/del5q/RCMD-(RS) | ||
RAEB-1/2 | 0.97 (0.75–1.25) | 0.8 | |
Transformed to AML | 1.28 (0.95–1.73) | 0.11 | |
Missing | 0.86 (0.6–1.24) | 0.4 | |
Disease status at HSCT | CR | ||
No CR | 1.31 (1.07–1.6) | 0.009 | |
Untreated | 0.85 (0.65–1.12) | 0.3 | |
Stem cell source | BM | ||
PB | 1.25 (0.97–1.6) | 0.088 | |
CMV serostatus patient | Negative | ||
Positive | 1.25 (1.03–1.52) | 0.026 | |
TBI | No | ||
Yes | 1.03 (0.8–1.33) | 0.8 | |
Sex match | Female to male | ||
Other combinations | 0.88 (0.73-1.07) | 0.2 | |
Conditioning intensity | Standard | ||
Reduced | 1.03 (0.85–1.26) | 0.7 |
B | Group | HR (95% CI) | p |
|---|---|---|---|
Donor (HD vs MSD) | <6 m | 2.59 (1.5–4.48) | <0.001 |
>6 m | 0.93 (0.42–2.07) | 0.9 | |
Donor age (dec) | <6 m | 0.99 (0.76–1.29) | 0.9 |
>6 m | 0.91 (0.63–1.33) | 0.6 | |
Donor x Donor age | <6 m | 0.88 (0.64–1.2) | 0.4 |
>6 m | 0.8 (0.53–1.19) | 0.3 | |
Patient age (dec) | 1.08 (0.93–1.25) | 0.3 | |
WHO classification | RA/RARS/del5q/RCMD-(RS) | ||
RAEB-1/2 | 1 (0.7–1.42) | >0.99 | |
Transformed to AML | 1.1 (0.71–1.71) | 0.7 | |
Missing | 0.71 (0.41–1.21) | 0.2 | |
Disease status at HCT | CR | ||
No CR | 1.41 (1.03–1.93) | 0.031 | |
Untreated | 1.45 (0.99–2.11) | 0.056 | |
Stem cell source | BM | ||
PB | 1.25 (0.87–1.8) | 0.2 | |
CMV serostatus patient | Negative | ||
Positive | 1.4 (1.04–1.88) | 0.026 | |
TBI | No | ||
Yes | 0.83 (0.56–1.21) | 0.3 | |
Sex match | Female to male | ||
Other combinations | 0.7 (0.54–0.91) | 0.009 | |
Conditioning intensity | Standard | ||
Reduced | 0.97 (0.73–1.28) | 0.8 |
C | Group | HR (95% CI) | p |
|---|---|---|---|
Donor (HD vs MSD) | <6 m | 1.16 (0.77–1.76) | 0.5 |
>6 m | 0.71 (0.4–1.25) | 0.2 | |
Donor age (dec) | <6 m | 1.05 (0.91–1.22) | 0.5 |
>6 m | 1.19 (1.01–1.4) | 0.037 | |
Donor x Donor age | <6 m | 0.88 (0.71–1.09) | 0.2 |
>6 m | 0.83 (0.63–1.09) | 0.17 | |
Patient age (dec) | 1.04 (0.94–1.16) | 0.5 | |
WHO classification | RA/RARS/del5q/RCMD-(RS) | ||
RAEB-1/2 | 0.96 (0.75–1.22) | 0.7 | |
Transformed to AML | 1.27 (0.95–1.7) | 0.11 | |
Missing | 0.89 (0.63–1.25) | 0.5 | |
Disease status at HCT | CR | ||
No CR | 1.16 (0.95–1.4) | 0.14 | |
Untreated | 0.82 (0.64–1.06) | 0.13 | |
Stem cell source | BM | ||
PB | 1.13 (0.89–1.44) | 0.3 | |
CMV serostatus patient | Negative | ||
Positive | 1.26 (1.05–1.52) | 0.015 | |
TBI | No | ||
Yes | 1.01 (0.8–1.29) | 0.9 | |
Sex match | Female to male | ||
Other combinations | 1.01 (0.84–1.22) | 0.9 | |
Conditioning intensity | Standard | ||
Reduced | 1.07 (0.89–1.28) | 0.5 |
D | Group | HR (95% CI) | p |
|---|---|---|---|
Donor (HD vs MSD) | <6 m | 0.56 (0.29–1.1) | 0.09 |
>6 m | 0.56 (0.25–1.27) | 0.17 | |
Donor age (dec) | <6 m | 1.03 (0.85–1.25) | 0.7 |
>6 m | 1.12 (0.9–1.39) | 0.3 | |
Donor x Donor age | <6 m | 0.87 (0.64–1.19) | 0.4 |
>6 m | 0.86 (0.58–1.26) | 0.4 | |
Patient age (dec) | 1.02 (0.88–1.18) | 0.8 | |
WHO classification | RA/RARS/del5q/RCMD-(RS) | ||
RAEB-1/2 | 0.92 (0.66–1.29) | 0.6 | |
Transformed to AML | 1.39 (0.94–2.05) | 0.097 | |
Missing | 1.02 (0.65–1.6) | 0.9 | |
Disease status at HCT | CR | ||
No CR | 1.04 (0.81–1.34) | 0.7 | |
Untreated | 0.52 (0.36–0.74) | <0.001 | |
Stem cell source | BM | ||
PB | 1.02 (0.74–1.42) | 0.9 | |
CMV serostatus patient | Negative | ||
Positive | 1.17 (0.92–1.5) | 0.2 | |
TBI | No | ||
Yes | 1.19 (0.87–1.62) | 0.3 | |
Sex match | Female to male | ||
Other combinations | 1.37 (1.06–1.78) | 0.016 | |
Conditioning intensity | Standard | ||
Reduced | 1.17 (0.91–1.5) | 0.2 |
E | Primary graft failure | Secondary graft failure | ||||
|---|---|---|---|---|---|---|
N | HR (95% CI) | p | HR (95% CI) | p | ||
Donor | MSD | 988 | ||||
HD | 334 | 3.56 (1.56–8.17) | 0.003 | 1.15 (0.55–2.4) | 0.7 | |
Conditioning intensity | Standard | 518 | ||||
Reduced | 804 | 0.9 (0.48–1.69) | 0.7 | 0.87 (0.49–1.56) | 0.6 | |
Stem cell source | BM | 205 | ||||
PB | 1117 | 0.71 (0.36–1.41) | 0.3 | 0.61 (0.31–1.21) | 0.16 | |
Patient age (decades) | 1322 | 1.08 (0.81–1.44) | 0.6 | 0.9 (0.69–1.18) | 0.5 | |
Donor age (decades) | 1322 | 0.81 (0.61–1.06) | 0.13 | 1.21 (0.93–1.58) | 0.15 | |
